29 October
Professor Masters discusses positive results announced by Eli Lilly on donanemab, showing a reduction in amyloid-related imaging abnormalities with edema/effusion (ARIA-E) from 15% in the standard treatment arm to 12% by titrating the drug. In patients heterozygous with APOE , ARIA-E incidence fell from 23% to 14% and in patients homozygous with APOE , incidence fell from 57% to 19% by using this dose titration method.
30 October
Professor Masters explained that some of the monoclonal antibodies against tau are beginning to show efficacy. Anti-MTBR tau antibody E2814 is being used in trials with patients with Dominantly Inherited Alzheimer's Disease and data shows the antibody is targeting a special region of tau which might result in slower spread of disease in the brain.
30 October
Professor Masters analyses an interesting report on real world data for lecanemab in Japan. The incidence of side effects appeared to be very low, 4.5% of ARIA-E which is much lower than in North American and Western Countries and this raises the question of why this is.